📊 VTGN Key Takeaways
Is Vistagen Therapeutics, Inc. (VTGN) a Good Investment?
Vistagen is a pre-clinical stage biotech company in severe financial distress with 54% YoY revenue collapse and $50.2M annual cash burn, leaving only ~1 year of runway despite $47.4M in cash reserves. With no revenue generation capability and operating losses exceeding $55M, the company faces critical funding pressure and dilution risk.
Why Buy Vistagen Therapeutics, Inc. Stock? VTGN Key Strengths
- Maintains $47.4M cash reserve to fund operations
- Zero debt burden eliminates leverage risk
- Strong current ratio of 4.67x provides short-term liquidity buffer
VTGN Stock Risks: Vistagen Therapeutics, Inc. Investment Risks
- Revenue collapsed 54% YoY on minimal $804K base; business fundamentals severely deteriorating
- Annual operating losses of $55.4M and cash burn of $50.2M implies ~1 year cash runway
- Extreme negative margins (-6891% operating, -6643% net) indicate pre-clinical stage with no viable commercial products
Key Metrics to Watch
- Monthly cash burn rate and months of runway remaining
- Revenue trends and clinical trial progress or product partnership announcements
- Financing activity and potential shareholder dilution events
Vistagen Therapeutics, Inc. (VTGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.67x current ratio provides a solid financial cushion.
VTGN Profit Margin, ROE & Profitability Analysis
VTGN vs Healthcare Sector: How Vistagen Therapeutics, Inc. Compares
How Vistagen Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vistagen Therapeutics, Inc. Stock Overvalued? VTGN Valuation Analysis 2026
Based on fundamental analysis, Vistagen Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vistagen Therapeutics, Inc. Balance Sheet: VTGN Debt, Cash & Liquidity
VTGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vistagen Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $-1.52 indicates the company is currently unprofitable.
VTGN Revenue Growth, EPS Growth & YoY Performance
VTGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $234.0K | -$10.7M | $-0.45 |
| Q2 2026 | $183.0K | -$10.7M | $-0.42 |
| Q1 2026 | $84.0K | -$10.7M | $-0.35 |
| Q3 2025 | $234.0K | -$6.4M | $-0.22 |
| Q2 2025 | $183.0K | -$6.6M | $-0.42 |
| Q1 2025 | $84.0K | -$6.9M | $-0.35 |
| Q3 2024 | $411.4K | -$6.3M | N/A |
| Q2 2024 | $277.7K | -$6.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vistagen Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VTGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vistagen Therapeutics, Inc. (CIK: 0001411685)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTGN
What is the AI rating for VTGN?
Vistagen Therapeutics, Inc. (VTGN) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTGN's key strengths?
Claude: Maintains $47.4M cash reserve to fund operations. Zero debt burden eliminates leverage risk.
What are the risks of investing in VTGN?
Claude: Revenue collapsed 54% YoY on minimal $804K base; business fundamentals severely deteriorating. Annual operating losses of $55.4M and cash burn of $50.2M implies ~1 year cash runway.
What is VTGN's revenue and growth?
Vistagen Therapeutics, Inc. reported revenue of $804.0K.
Does VTGN pay dividends?
Vistagen Therapeutics, Inc. does not currently pay dividends.
Where can I find VTGN SEC filings?
Official SEC filings for Vistagen Therapeutics, Inc. (CIK: 0001411685) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTGN's EPS?
Vistagen Therapeutics, Inc. has a diluted EPS of $-1.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VTGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vistagen Therapeutics, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VTGN stock overvalued or undervalued?
Valuation metrics for VTGN: ROE of -104.9% (sector avg: 15%), net margin of -6,643.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VTGN stock in 2026?
Our dual AI analysis gives Vistagen Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTGN's free cash flow?
Vistagen Therapeutics, Inc.'s operating cash flow is $-50.2M, with capital expenditures of $0.0. FCF margin is -6,248.3%.
How does VTGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,643.2% (avg: 12%), ROE -104.9% (avg: 15%), current ratio 4.67 (avg: 2).